A Phase 2 interventional study of SLN12140 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Linno Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Linno Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to learn if drug SLN12140 works to treat Complement Inhibitor-Naïve Subjects with Paroxysmal Nocturnal Hemoglobinuria in adults. It will also learn about the safety, pharmacokinetic characteristics, and dosing of drug SLN12140.
The study is divided into four phases: screening period, core treatment period, extended dosing period, and follow-up period, and includes two cohorts (Cohorts 1-2), with each cohort enrolling at least 5 treatment-naïve adult PNH subjects for complement inhibitor therapy.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
This study's planned enrollment of 10 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Browse Hemoglobinuria, Paroxysmal studies →Linno Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks
Drug: SLN12140
5 participants will receive SLN12140 100mg QW for 4 weeks, then 300mg QW for 8 weeks, then 200mg QW for 52 weeks. 5 participants will receive SLN12140 200mg QW for 4 weeks, then 600mg Q4W for 60 weeks
During the 12-week treatment period, the proportion of participants whose Lactate Dehydrogenase (LDH) decreased by 60% or more from baseline or whose LDH was below the upper limit
To assess efficacy of SLN12140 in participants with PNH
Time frame: 12weeks after baseline
Percentage change of LDH from baseline
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Proportion of participants achieving hemolysis control (LDH ≤ 1.5×ULN)
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Change in hemoglobin (Hb) levels from baseline
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through week 64
The proportion of participants whose hemoglobin (Hb) increased by ≥2 g/dL from baseline and who avoided blood transfusion
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Proportion of participants who avoided blood transfusion
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Incidence(%) of Breakthrough Hemolysis (BTH)
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Changes from baseline in intravascular and extravascular hemolysis indicators (including but not limited to reticulocytes, bilirubin, red blood cell count, platelet count, ferritin, etc.)
To assess the efficacy of SLN12140 in participants with PNH
Time frame: baseline through week 64
Changes in thrombus formation risk markers from baseline (including but not limited to fibrinogen, prothrombin time, activated partial thromboplastin time, thrombin time, fibrin D-dimer, etc.);
To assess the efficacy of SLN12140 in participants with PNH
Time frame: Baseline through week 64
Change in functional assessment of Functional Assessment of Chronic Illness Therapy (FACIT)
To assess the efficacy of SLN12140 in participants with PNH. FACIT is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function to assess the Impact of SLN12140 on Treatment-Related Outcomes. The minimum value is 0 and maximum value is 52, and higher scores mean a worse outcome.
Time frame: Baseline through Week 64
Number(%) of participants with Adverse Events (AEs) , Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
To assess the safety and tolerability of SLN12140 in participants with PNH
Time frame: Baseline through Week 64
Pharmacokinetics (PK)parameters of SLN12140: Area Under The Plasma Concentration-time Curve
To characterize the pharmacokinetics of SLN12140 in participants with PNH
Time frame: Baseline through week 64 (predose and postdose)
Immunegenicity in Paraxysmal Nocturnal Hemoglobinuria
Determine anti-drug antibody titers
Time frame: Baseline through Week 64
PK: Maximum Plasma Concentration (Cmax)
To characterize the pharmacokinetics of SLN12140 in participants with PNH
Time frame: Baseline through week 64( predose and postdose)
PK: Time To Maximum Concentration (Tmax)
To characterize the pharmacokinetics of SLN12140 in participants with PNH
Time frame: Baseline through week 64( predose and postdose)
Complement Alternative Pathway (AP) Functional Activity
Serum AP functional activity was measured by the Wieslab functional immunoassay method.
Time frame: Baseline through week 64( predose and post dose)
Complement FP
Plasma FP was measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline through week 64(predose and postdose)
No study locations are listed for this record.
Plan to share: Undecided — It is not decided yet at this moment if we will share IPD with other researchers, or when will IPD will be shared, or with whom will IPD be shared, or by what mechanism will IPD be shared.
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Jul 2026, 5 months later.
Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's planned 5 months is below that.
Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SLN12140
Linno Pharmaceuticals, Inc.